C-erbB-2 clone MXR011 also known as Her-2/neu

Rabbit Monoclonal Antibody

Instruction for Use

Specification:
C-erbB2 (also called Her-2/neu, ERBB2 or neu) is a transmembrane receptor tyrosine kinase. HER-2 is considered as the target oncogene driving the amplification, so that its activation will causes malignant transformation and increases the malignant potential (cell proliferation, invasiveness etc.) of the cells. Amplification of C-erbB2 gene invariably leads to over-expression of its protein product. Over-expressed C-erbB protein disturbs the HER-receptor family signalling networks, i.e. signaling mediated via EGFR receptor

Availability:

Catalog No.	Contents	Volume
ILM0110-C01	C-erbB-2	0,1 ml concentrate
ILM0110-C05	C-erbB-2	0,5 ml concentrate
ILM0110-C1	C-erbB-2	1,0 ml concentrate



Intended use: For Research Use Only

Reactivity: Human, others not known

Clone: MXR011

Species of origin: Rabbit

Isotype: IgG

Control Tissue: Breast carcinoma

Staining: Membranous

Presentation: Supernatant contains 15mM sodium Azide

Application and suggested dilutions:
Pre-treatment: Heat induced epitope retrieval in 10 mM citrate buffer pH6.0 for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution up to 1:100-1:200)

The optimal dilution for a specific application should be determined by the investigator.

Note: Dilution of the antibody in 10% normal goat serum followed by a Goat anti-Rabbit secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

Reference:

1) Owens, MA Horten, BC, Da Silva MM. Her2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clinical breast cancer, 2004,5(1) 63-69
2) Gibbons-Fideler IS, Nitta H, Murillo A et al. Identification of Her2 immunohistochemistry-negative fish-amplified breast cancers and their response to anti-her2 neoadjuvant chemotherapy. Am J Clin Pathol, 2019, 151(2) 176-184